Development of triamcinolone pharmaceutical gummies for the treatment of oral lichen planus
Carlos Torrado-Salmerón – Associate Professor, Faculty of Pharmacy, Complutense University; Víctor Guarnizo-Herrero – Assistant Professor, Faculty of Pharmacy, University of Alcalá; Borja Martínez-Alonso – PhD Student, Faculty of Pharmacy, University of Alcalá; Hugo Pardo – PhD Student, Faculty of Pharmacy, University of Alcalá; Norma Sofía Torres Pabón – Assistant Professor, Faculty of Pharmacy, University of Alcalá; Guillermo Torrado Durán – Professor, Faculty of Pharmacy, University of Alcalá
Student Complutense University of Madrid Madrid, Madrid, Spain
Introduction: Oral lichen planus is a chronic inflammatory autoimmune disease of the oral mucosa that represents a therapeutic challenge due to its persistence, recurrence, and potential progression to carcinoma. The current mainstay of treatment is triamcinolone, which is commercially available in topical formulations such as ointments (1). In this study, a novel drug delivery system for this active compound is proposed: pharmaceutical gummies formulated using gelatin and a natural gum (xanthan gum) as base materials (2).
Learning Objectives:
To evaluate the influence of glycerin on the texture properties of pharmaceutical gummies.
To optimize the proportions of xanthan gum within the gummy matrix.
To compare drug release profiles among the different gummy formulations.
